Chesley Taft & Associates LLC reduced its stake in shares of Celgene Co. (NASDAQ:CELG) by 0.5% during the first quarter, Holdings Channel reports. The firm owned 179,971 shares of the biopharmaceutical company’s stock after selling 852 shares during the period. Celgene accounts for about 2.1% of Chesley Taft & Associates LLC’s holdings, making the stock its 7th largest position. Chesley Taft & Associates LLC’s holdings in Celgene were worth $22,394,000 as of its most recent SEC filing.

Several other institutional investors also recently made changes to their positions in the stock. Stock Yards Bank & Trust Co. boosted its position in shares of Celgene by 0.7% in the first quarter. Stock Yards Bank & Trust Co. now owns 116,635 shares of the biopharmaceutical company’s stock valued at $14,513,000 after buying an additional 848 shares during the period. Douglass Winthrop Advisors LLC boosted its position in shares of Celgene by 7.0% in the first quarter. Douglass Winthrop Advisors LLC now owns 15,324 shares of the biopharmaceutical company’s stock valued at $1,907,000 after buying an additional 1,000 shares during the period. S&CO Inc. boosted its position in shares of Celgene by 0.5% in the first quarter. S&CO Inc. now owns 12,365 shares of the biopharmaceutical company’s stock valued at $1,539,000 after buying an additional 65 shares during the period. Charter Trust Co. boosted its position in shares of Celgene by 55.2% in the first quarter. Charter Trust Co. now owns 3,781 shares of the biopharmaceutical company’s stock valued at $470,000 after buying an additional 1,345 shares during the period. Finally, CHURCHILL MANAGEMENT Corp boosted its position in shares of Celgene by 95.1% in the first quarter. CHURCHILL MANAGEMENT Corp now owns 41,196 shares of the biopharmaceutical company’s stock valued at $5,126,000 after buying an additional 20,077 shares during the period. Institutional investors own 77.68% of the company’s stock.

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Celgene Co. (NASDAQ:CELG) opened at 123.27 on Friday. The company has a market cap of $95.90 billion, a price-to-earnings ratio of 49.51 and a beta of 1.74. Celgene Co. has a 52-week low of $94.42 and a 52-week high of $127.64. The firm’s 50-day moving average price is $124.35 and its 200-day moving average price is $116.33.

Celgene (NASDAQ:CELG) last posted its quarterly earnings results on Thursday, January 26th. The biopharmaceutical company reported $1.61 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.59 by $0.02. Celgene had a net margin of 17.80% and a return on equity of 77.95%. The firm earned $2.98 billion during the quarter, compared to the consensus estimate of $3.03 billion. During the same quarter in the previous year, the firm posted $1.18 earnings per share. The company’s revenue was up 16.3% on a year-over-year basis. On average, equities analysts anticipate that Celgene Co. will post $7.23 EPS for the current year.

COPYRIGHT VIOLATION WARNING: This piece of content was first reported by Watch List News and is the sole property of of Watch List News. If you are reading this piece of content on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright legislation. The correct version of this piece of content can be viewed at https://www.watchlistnews.com/chesley-taft-associates-llc-has-22-394-million-position-in-celgene-co-celg/1206855.html.

Several brokerages have recently weighed in on CELG. Robert W. Baird reiterated an “outperform” rating and issued a $162.00 price target on shares of Celgene in a research report on Wednesday. Jefferies Group LLC reiterated a “buy” rating and issued a $154.00 price target on shares of Celgene in a research report on Tuesday, April 11th. Oppenheimer Holdings Inc. reiterated an “outperform” rating and issued a $148.00 price target on shares of Celgene in a research report on Wednesday, April 5th. Cann reiterated a “buy” rating and issued a $148.00 price target on shares of Celgene in a research report on Tuesday, April 4th. Finally, Leerink Swann reiterated a “market perform” rating on shares of Celgene in a research report on Monday, March 20th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and twenty-four have assigned a buy rating to the company’s stock. Celgene has a consensus rating of “Buy” and a consensus price target of $139.46.

In related news, insider Rupert Vessey sold 4,000 shares of the business’s stock in a transaction that occurred on Wednesday, March 1st. The shares were sold at an average price of $124.42, for a total value of $497,680.00. Following the completion of the transaction, the insider now owns 778 shares of the company’s stock, valued at $96,798.76. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Gilla Kaplan sold 14,033 shares of the business’s stock in a transaction that occurred on Thursday, March 30th. The stock was sold at an average price of $123.83, for a total transaction of $1,737,706.39. Following the completion of the transaction, the director now directly owns 73,109 shares of the company’s stock, valued at approximately $9,053,087.47. The disclosure for this sale can be found here. Insiders own 0.97% of the company’s stock.

About Celgene

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

5 Day Chart for NASDAQ:CELG

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).

Receive News & Ratings for Celgene Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Co. and related companies with Analyst Ratings Network's FREE daily email newsletter.